Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04935229 · ClinicalTrials.gov registry record · Phase 1
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
A Phase 1 study, sponsored by TriSalus Life Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT04935229 is a Phase 1 study that was terminated before completion, run by TriSalus Life Sciences. The registered enrollment target is 67 participants.
The verdict
NCT04935229, a Phase 1 study, was terminated before completion, sponsored by TriSalus Life Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- DRUG SD-101
- BIOLOGICAL Nivolumab and Relatlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2024-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04935229
The ClinicalTrials.gov registry entry for NCT04935229 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TriSalus Life Sciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT04935229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04935229 about?
NCT04935229 is a clinical study titled "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma". This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.
What is the current status of trial NCT04935229?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2021-08-02. Estimated completion is 2024-07-17.
What interventions are being tested in trial NCT04935229?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), SD-101 (DRUG), Nivolumab and Relatlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04935229?
This trial is sponsored by TriSalus Life Sciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.